Increased use of acid-suppressing drugs before the occurrence of ischemic events: A potential source of confounding in recent observational studies

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 985-993

  Blackburn, David F ^a   Lamb, Darcy A ^b   Mcleod, Melanie M ^c   Eurich, Dean T ^d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SASKATOON HEALTH REGION   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clopidogrel; H 2RA; Histamine2 receptor antagonist; Myocardial infarction; PPI; Proton pump inhibitor; Unstable angina

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLOPIDOGREL; CORTICOSTEROID; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; RECURRENT DISEASE; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC STUDIES; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RESEARCH DESIGN; RISK FACTORS; TICLOPIDINE; TIME FACTORS;

EID: 77957669777     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.985     Document Type: Article

References (19)

1. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
2. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18.
3. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (proton pump inhibitors and clopidogrel association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-53.
4. Small D, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84. (Pubitemid 351389118)
5. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5.
6. Evanchan J, Donnally MR, Binkely P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol 2010;33:168-71.
7. Gaglia MA Jr, Troguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug eluting stents to outcomes. Am J Cardiol 2010;105:833-8.
8. Kwok CS, Loke YK. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31: 810-23.
9. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clincal efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97.
10. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9.
11. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337-45.
12. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010;26:e54-7.
13. Lamb DA, Eurich DT, McAlister FA, et al. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes 2009;2:228-35.
14. Blackburn DF, Lamb DA, Eurich DT, et al. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens 2007;25:1499-505.
15. Eurich DT, Sadowdsky CA, Simpson SH, Marrie TJ, Majumdar. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010; 123:47-53.
16. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61: e59-64.
17. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
18. Von Korf M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45: 197-203.
19. Johansson S, Wallander MA, Ruigomez A, Rodriguez LAG. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? Aliment Pharmacol Ther 2003;18:973-8.